Plasma concentrations of active simvastatin acid are increased by gemfibrozil

Impact of OATP transporters on pharmacokinetics

Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 994 · see citing works

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · see citing works

Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance

Neuvonen, P. J., Niemi, M., & Backman, J. T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 862 · see citing works

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 636 · see citing works

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions

Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 574 · see citing works

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

Davidson, M. H., Mcgarry, T. F., Bettis, R. B., Melani, L., Lipka, L., LeBeaut, A., Suresh, R., Sun, S. H., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 557 · see citing works

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470 · see citing works

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463 · see citing works

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 410 · see citing works

Safety considerations with fibrate therapy

Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408 · see citing works

Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil

Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407 · see citing works

EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS

Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336 · see citing works

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 339 · see citing works

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper‐DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332 · see citing works

Effects of Fibrates on Metabolism of Statins in Human Hepatocytes

Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 323 · see citing works

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

Kasiske, B., Cosío, F., Beto, J., Bolton, K., Chavers, B., Grimm, R., Levin, A., Masri, B., Parekh, R., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 338 · see citing works

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Schneck, D. W. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292 · see citing works

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 285 · see citing works

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 285 · see citing works

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

Melani, L. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00803-5 · Cited by 271 · see citing works

Role of OATP Transporters in the Disposition of Drugs

Niemi, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.787 · Cited by 266 · see citing works

Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

Backman, J. T., Filppula, A. M., Niemi, M., & Neuvonen, P. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011411 · Cited by 241 · see citing works

Clinical Perspectives of Statin-Induced Rhabdomyolysis

Antons, K., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 237 · see citing works

Phenotype standardization for statin-induced myotoxicity

Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Carr, D. F., Bloch, K. M., Fahy, J., Hanson, A., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.121 · Cited by 220 · see citing works

Role of transporters in drug interactions

Han, H. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-1107-y · Cited by 220 · see citing works

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2004) · Xenobiotica · doi:10.1080/00498250310001646353 · Cited by 219 · see citing works

Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

Neuvonen, P. J., Backman, J. T., & Niemi, M. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847070-00003 · Cited by 217 · see citing works

Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle

Evans, M., & Rees, A. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00004 · Cited by 211 · see citing works

Cyclosporine markedly raises the plasma concentrations of repaglinide

Kajosaari, L. I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.005 · Cited by 207 · see citing works

Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial

Goldberg, A. C., Sapre, A., Liu, J., Capece, R., & Mitchel, Y. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.5.620 · Cited by 191 · see citing works

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189 · see citing works

Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes

Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189 · see citing works

The role of transporters in drug interactions

Endres, C. J., Hsiao, P., Chung, F. S., & Unadkat, J. D. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.11.002 · Cited by 184 · see citing works

Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin

Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_157.x · Cited by 172 · see citing works

Transporter-Mediated Drug–Drug Interactions

Müller, F., & Fromm, M. F. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.44 · Cited by 172 · see citing works

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 166 · see citing works

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

Backman, J. T., Luurila, H., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.007 · Cited by 155 · see citing works

Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle

Sirvent, P., Mercier, J., Vassort, G., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.070 · Cited by 154 · see citing works

Pharmacologic characteristics of statins

McKenney, J. M. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261507 · Cited by 154 · see citing works

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139 · see citing works

Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro

Skottheim, I. B., Gedde‐Dahl, A., Hejazifar, S., Hoel, K., & Åsberg, A. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.12.009 · Cited by 137 · see citing works

Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor

Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136 · see citing works

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

Gertz, M., Houston, J. B., & Galetin, A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039248 · Cited by 135 · see citing works

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

Davidson, M. H., Ballantyne, C. M., Kerzner, B., Melani, L., Sager, P. T., Lipka, L., Strony, J. T., Suresh, R., & Veltri, E. P. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00289.x · Cited by 135 · see citing works

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach

Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Houston, J. B., & Tremaine, L. M. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.004 · Cited by 134 · see citing works

Risk of adverse events with fibrates*

Alsheikh-Ali, A. A. A., Kuvin, J. T., & Karas, R. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.033 · Cited by 125 · see citing works

Statin myotoxicity: a review of genetic susceptibility factors

Needham, M., & Mastaglia, F. L. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.09.011 · Cited by 108 · see citing works

Fenofibrate: treatment of hyperlipidemia and beyond

Rosenson, R. S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1319 · Cited by 110 · see citing works

Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects

Fahrmayr, C., Fromm, M. F., & König, J. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491683 · Cited by 108 · see citing works

Transporter-Mediated Drug-Drug Interactions and Their Significance

Liu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_5 · Cited by 109 · see citing works

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 108 · see citing works

Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid

Uçar, M., Neuvonen, M., Luurila, H., Dahlqvist, R., Neuvonen, P. J., & Mj�rndal, T. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0700-5 · Cited by 107 · see citing works

Learning from the cerivastatin experience

Farmer, J. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06489-3 · Cited by 105 · see citing works

The myotoxicity of statins

Evans, M., & Rees, A. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200208000-00009 · Cited by 104 · see citing works

Combination therapy for dyslipidemia: safety and regulatory considerations

Davidson, M. H. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02970-3 · Cited by 104 · see citing works

Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin

Igel, M., Sudhop, T., & von Bergmann, K. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401102731 · Cited by 100 · see citing works

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268044 · Cited by 97 · see citing works

The Interference of Pharmaceuticals with Endogenous and Xenobiotic Metabolizing Enzymes in Carp Liver: An In-Vitro Study

Thibaut, R., Schnell, S., & Porte, C. (2006) · Environmental Science & Technology · doi:10.1021/es0607483 · Cited by 96 · see citing works

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

Niemi, M., Kajosaari, L. I., Neuvonen, M., Backman, J. T., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02027.x · Cited by 95 · see citing works

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

Yamazaki, M., LI, B., Louie, S. W., Pudvah, N. T., Stocco, R., Wong, W., Abramovitz, M., Demartis, A., Laufer, R., Hochman, J. H., et al. (2005) · Xenobiotica · doi:10.1080/00498250500136676 · Cited by 95 · see citing works

The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

Tornio, A., Niemi, M., Neuvonen, M., Laitila, J., Kalliokoski, A., Neuvonen, P. J., & Backman, J. T. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.34 · Cited by 92 · see citing works

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

Niemi, M., Tornio, A., Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Backman, J. T. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0133-z · Cited by 88 · see citing works

Pharmacogenomics of cholesterol-lowering therapy

Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 85 · see citing works

Pharmacological interactions of statins

Paoletti, R., Corsini, A., & Bellosta, S. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(02)00002-8 · Cited by 85 · see citing works

Efficacy and safety of rosuvastatin in treatment of dyslipidemia

McKenney, J. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1033 · Cited by 83 · see citing works

Fibrates in Combination With Statins in the Management of Dyslipidemia

Jacobson, T. A., & Zimmerman, F. H. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05278.x · Cited by 82 · see citing works

Use of Fibrates in the United States and Canada

Jackevicius, C. A. (2011) · JAMA · doi:10.1001/jama.2011.353 · Cited by 82 · see citing works

Drug–drug interactions that interfere with statin metabolism

Hirota, T., & Ieiri, I. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1056149 · Cited by 84 · see citing works

Statins and myotoxicity: a therapeutic limitation

Tiwari, A. K., Bansal, V. S., Chugh, A., & Mookhtiar, K. A. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.651 · Cited by 80 · see citing works

HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells

Skaletz‐Rorowski, A. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00618-1 · Cited by 79 · see citing works

Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity

Seachrist, J. L., Loi, C., Evans, M. G., Criswell, K. A., & Rothwell, C. E. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi305 · Cited by 77 · see citing works

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

Davidson, M. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.145 · Cited by 76 · see citing works

In vitroevidence for the role of OATP and OCT uptake transporters in drug–drug interactions

Kindla, J., Fromm, M. F., & König, J. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902911463 · Cited by 74 · see citing works

Multiple Inhibition Mechanisms and Prediction of Drug–Drug Interactions: Status of Metabolism and Transporter Models as Exemplified by Gemfibrozil–Drug Interactions

Hinton, L. K., Galetin, A., & Houston, J. B. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9446-6 · Cited by 73 · see citing works

Comparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes

Prueksaritanont, T., Richards, K. M., Qiu, Y., Strong-Basalyga, K., Miller, A. R., Li, C., Eisenhandler, R., & Carlini, E. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9011-5 · Cited by 73 · see citing works

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide

Re, M. D., Fogli, S., Derosa, L., Massari, F., SOUZA, P. D., Crucitta, S., Sergio Bracarda, A., Santini, D., & Danesi, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.001 · Cited by 70 · see citing works

Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide

Varma, M. V. S., Lin, J., Bi, Y., Kimoto, E., & Rodrigues, A. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064303 · Cited by 69 · see citing works

Pharmacokinetic Interactions Between Statins and Fibrates

Corsini, A., Bellosta, S., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.007 · Cited by 69 · see citing works

Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

Becquemont, L., Neuvonen, M., Verstuyft, C., Jaillon, P., Letierce, A., Neuvonen, P. J., & Funck‐Brentano, C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100098 · Cited by 64 · see citing works

Fibrates: What Have We Learned in the Past 40 Years?

Backes, J. M., Gibson, C., Ruisinger, J. F., & Moriarty, P. M. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.412 · Cited by 63 · see citing works

Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF ‐1α‐induced pro‐angiogenic factor

Wang, J., Li, X., Sun, X., Li, G., Sun, J., Ye, Y., Cong, L., Li, W., Lu, S., Feng, J., et al. (2018) · Cancer Science · doi:10.1111/cas.13570 · Cited by 61 · see citing works

Combination statin-fibrate therapy: safety aspects

Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00917.x · Cited by 60 · see citing works

Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review

Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58 · see citing works

Role of transport proteins in drug discovery and development: a pharmaceutical perspective

Ayrton, A. D., & Morgan, P. (2008) · Xenobiotica · doi:10.1080/00498250801923855 · Cited by 58 · see citing works

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

Niemi, M., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)84578-1 · Cited by 57 · see citing works

CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast

Karonen, T., Neuvonen, P. J., & Backman, J. T. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04086.x · Cited by 55 · see citing works

Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic Patients

Schuster, H. (2003) · Cardiology · doi:10.1159/000070669 · Cited by 55 · see citing works

Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

Whitfield, L. R., Porcari, A. R., Alvey, C. W., Abel, R. B., Bullen, W., & Hartman, D. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010366446 · Cited by 54 · see citing works

Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins

Sharma, P. K., Butters, C., Smith, V., Elsby, R., & Surry, D. D. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.003 · Cited by 53 · see citing works

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

Fenner, K. S., Jones, H. M., Ullah, M., Kempshall, S., Dickins, M., Lai, Y., Morgan, P., & Barton, H. A. (2011) · Xenobiotica · doi:10.3109/00498254.2011.626464 · Cited by 53 · see citing works

Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid

Goosen, T. C., Bauman, J. N., Davis, J. A., Yu, C., Hurst, S. I., Williams, J. A., & Loi, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015230 · Cited by 52 · see citing works

Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia

Jacobson, T. A. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00005 · Cited by 51 · see citing works

Lipid-lowering effects of statins: a comparative review

Davidson, M. H., & Robinson, J. G. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.13.1701 · Cited by 51 · see citing works

Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial Cells at therapeutic concentrations

Murtola, T. J., Pennanen, P. T., Syvälä, H., Bläuer, M., Ylikomi, T. J., & Tammela, T. L. J. (2009) · The Prostate · doi:10.1002/pros.20951 · Cited by 49 · see citing works

Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs

Xu, Y., Zhou, Y., Hayashi, M., Shou, M., & Skiles, G. L. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038067 · Cited by 47 · see citing works

Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors

Khurana, V., Minocha, M., Pal, D., & Mitra, A. K. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0062 · Cited by 46 · see citing works

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters

Tornio, A., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1227791 · Cited by 46 · see citing works

Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

Bernsdorf, A., Gießmann, T., Modeß, C., Wegner, D., Igelbrink, S., Hecker, U., Haenisch, S., Cascorbi, I., Terhaag, B., & Siegmund, W. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02599.x · Cited by 45 · see citing works

Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy

Shyamsundar, M., McAuley, D. F., Shields, M. O., MacSweeney, R. E., Duffy, M. J., Johnston, J. R., McGuigan, J., Backman, J. T., Calfee, C. S., Matthay, M. A., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31829d686b · Cited by 45 · see citing works

A Neuromuscular Approach to Statin-Related Myotoxicity

Baker, S. K., & Samjoo, I. A. (2008) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007514 · Cited by 45 · see citing works

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191 · see citing works

Gemfibrozil greatly increases plasma concentrations of cerivastatin

Backman, J. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 337 · see citing works

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Schneck, D. W. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292 · see citing works

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189 · see citing works

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 285 · see citing works